The Efficacy and Safety of Sunitinib in Korean Patients with Advanced Renal Cell Carcinoma: High Incidence of Toxicity Leads to Frequent Dose Reduction-Reference-Cited by-同舟云学术

The Efficacy and Safety of Sunitinib in Korean Patients with Advanced Renal Cell Carcinoma: High Incidence of Toxicity Leads to Frequent Dose Reduction

Published:2010-05-10 Issue:10 Volume:40 Page:980-985
ISSN:0368-2811
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:Japanese Journal of Clinical Oncology

Author:

Yoo C.,Kim J. E.,Lee J.-L.,Ahn J.-H.,Lee D. H.,Lee J.-S.,Na S.,Kim C.-S.,Hong J. H.,Hong B.,Song C.,Ahn H.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://academic.oup.com/jjco/article-pdf/40/10/980/5121835/hyq073.pdf

Reference26 articles.

1. Global Cancer Statistics, 2002

2. Renal-Cell Carcinoma

3. Overproduction of Vascular Endothelial Growth Factor Related to von Hippel-Lindau Tumor Suppressor Gene Mutations and Hypoxia-Inducible Factor-1α Expression in Renal Cell Carcinomas.

4. Biology and Clinical Development of Vascular Endothelial Growth Factor–Targeted Therapy in Renal Cell Carcinoma

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 2/1 dose schedule of sunitinib is superior than the 4/2 regimen for the first-line therapy of clear cell metastatic renal cell carcinoma – An Indian experience;Indian Journal of Cancer;2023-10

2. The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study;Cancers;2023-02-02

3. Sunitinib therapy for imatinib-resistant and/or intolerant gastrointestinal stromal tumors: comparison of safety and efficacy between standard and reduced dosage regimens;Japanese Journal of Clinical Oncology;2023-01-14

4. Prognostic factors for overall survival in patients with clear cell metastatic renal cell carcinoma;Medicine;2021-08-06

5. Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma;Cancer Management and Research;2021-08